CIIE Direct Hit: AI Reshapes the Health Ecosystem

On November 5th, the 8th China International Import Expo officially opened, becoming an important window to observe the industrial innovation achievements of companies in the big health sector.

From on-site contract signing at the expo to product displays, from the source innovation in drug research and development to the inclusive implementation of terminal health services, AI is reconstructing the health industry ecosystem with a posture of "full-chain penetration and multi-scenario integration."

According to reports, the organ-on-a-chip company YaoSu Technology has reached a drug research and development cooperation with Medicilon, JD HEALTH's intelligent matrix makes health services more accessible, YingKang YiSheng's future hospital solution makes diagnosis and treatment more precise, and Bloomage Biotech's "AI + ECM" research makes anti-aging more scientific.

These practices collectively prove that AI is no longer an "auxiliary tool" in the health industry but rather the "core engine" driving industrial upgrades.

As a "connector" of global technology, the Import Expo is accelerating the transformation of these AI innovations from exhibits to commodities, moving from single-point breakthroughs to ecological collaboration.

With the continuous iteration and implementation of technology, the future health ecosystem will be more efficient, precise, and inclusive, allowing everyone to enjoy the health dividends brought by technological progress.

This revolution in reconstructing the health ecosystem through AI has just begun.

Breaking the Pain Points of Innovation Efficiency

AI is reshaping the innovation paradigm of the health industry from the source, whether it is cost reduction and efficiency improvement in drug research and development or scientific breakthroughs in the anti-aging field, both are inseparable from the deep integration of technology and AI.

On November 6th, the "AI + organ-on-a-chip" company YaoSu Technology reached a strategic cooperation with the CRO company Medicilon at the Import Expo, becoming a typical case of innovation on the research and development side.

This cooperation will integrate YaoSu Technology's cutting-edge technology in the organ-on-a-chip field with Medicilon's internationally standardized large-scale research and development service system, jointly building a new generation of drug research and development platform that is more predictive and efficient.

Among them, YaoSu Technology and Medicilon will cooperate in three major directions: co-building an organ-on-a-chip research and service platform, organ-on-a-chip-DMPK pharmacokinetic prediction joint technology, and pharmacology-pharmacodynamics-organ-on-a-chip AI joint solutions.

According to reports from YaoSu Technology, they will further implement cooperation with diagnostic companies and biochip companies to further promote the application of organ-on-a-chip technology.

The cooperation between the "AI + organ-on-a-chip" company and the CRO company precisely addresses the efficiency pain points of traditional drug research and development, and is expected to bring more innovations to the research and development side.

This also aligns with the current policy direction.

In April of this year, the Ministry of Industry and Information Technology and six other departments issued the "Implementation Plan for the Digital and Intelligent Transformation of the Pharmaceutical Industry (2025-2030)," which distilled 41 typical scenarios for technological innovation development, providing references for the digital and intelligent transformation of pharmaceutical companies.

Among them, it mentioned "animal model data mining and virtual animal experiments," which addresses issues such as high demand for animal alternatives and discrepancies in consistency with human results, utilizing data mining and simulation technology to establish computer simulation models for animal modeling.

In the forefront of anti-aging, Bloomage Biotech is promoting ECM (extracellular matrix) research through a "30 billion-level molecular database + AI research and development platform." As one of the few companies globally to systematically layout key ECM materials, Bloomage Biotech relies on AI technology to achieve research from molecules to systems, promoting the advancement of anti-aging concepts from single substances to systemic structures.

With the changes in ECM being listed as the 13th major aging marker by Cell in 2025, Bloomage Biotech's AI-driven R&D system is expected to bring more possibilities for anti-aging products.

According to information from Xinfeng, Bloomage Biotech has planned to establish a regional center in Europe to achieve "nearshore manufacturing" for rapid response to global market demands.

In the future, as such innovative collaborations continue to deepen and materialize, AI is expected to further break down R&D boundaries, enhance innovation conversion efficiency, and bring more disruptive breakthroughs to the health industry, accelerating the transformation of the industry and injecting lasting momentum into the high-quality development of the global health sector.

AI + Full-Scene Coverage

If the R&D side represents the deep innovation of AI, the service side reflects the broad implementation of AI. From online inclusive services to precise in-hospital diagnosis and treatment, AI is making health services more accessible and efficient.

JD HEALTH's intelligent service matrix showcased at the Import Expo is quite representative.

It is understood that JD HEALTH, relying on the "Jingyi Qianxun" large model, has created more than 10 types of professional service intelligences, including AI doctors, AI pharmacists, and AI nutritionists, and has incorporated over 1,000 expert doctors from top-tier hospitals to provide 24/7 online triage, consultations, report interpretations, and other services.

According to further information from JD HEALTH, the "Jingyi Qianxun" large model can strictly simulate the clinical diagnostic thinking pathways of doctors, deeply integrating medical knowledge systems with real diagnostic logic, actively introducing and aligning external evidence-based medical evidence during the reasoning process to ensure that the reasoning conforms to medical consensus, helping doctors make more accurate judgments on complex conditions.

The intelligent service matrix showcased by JD HEALTH at the Import Expo is a microcosm of deeply integrating cutting-edge AI technology into the entire chain of medical health services, which is expected to promote the evolution of medical services towards a more intelligent and inclusive direction.

In the in-hospital scenario, Yingkang Yisheng's "AI + Medical" solution reconstructs the entire diagnostic and treatment process.

Yingkang Yisheng focuses on core scenarios such as "AI + Medical Services," "AI + Tumor Diagnosis and Treatment," and "AI + Smart Medication," launching innovative products like intelligent consultations, digital mammography machines, and tumor infusion robots.

Taking the "AI + Tumor Diagnosis and Treatment" scenario as an example, Yingkang Yisheng's AI-based tumor full-cycle management system integrates data from early screening, diagnosis, treatment to rehabilitation, providing patients with personalized comprehensive service plans that include nutritional support, pain management, and more, promoting a shift in tumor diagnosis and treatment towards a patient-centered approach.

With the deep integration of technology and scenarios, AI is expected to continue to play a powerful empowering role, driving significant improvements in the accessibility, precision, and safety of medical services